Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adolescents and Adults

Trial Profile

Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adolescents and Adults

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
  • Indications Meningitis; Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Meningococcal infections; Meningococcal meningitis
  • Focus Pharmacodynamics; Registrational
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 28 Jun 2017 Planned End Date changed from 1 Mar 2017 to 20 Dec 2017.
    • 28 Jun 2017 Planned primary completion date changed from 1 Mar 2017 to 20 Dec 2017.
    • 28 Jun 2017 Status changed from completed to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top